Article Text

Download PDFPDF

2022-RA-367-ESGO Rucaparib in clinical practice – what are the elements of patient adherence?
  1. Elena-Ioana Braicu1,
  2. Zaher Halwani2,
  3. Dario Zocholl3,
  4. Jessica Dysarz4,
  5. Hans-Martin Enzinger5,
  6. Moritz Hamann6,
  7. Martin Peters7,
  8. Helmut Forstbauer8,
  9. Steffi Busch9 and
  10. Jalid Sehouli1
  1. 1Klinik für Gynäkologie, Charité Universitätsmedizin Berlin, Berlin, Germany
  2. 2Klinik für Gynäkologie und Geburtsmedizin, Vivantes Humboldt-Klinikum, Berlin, Germany
  3. 3Institute of Biometry and Clinical Epidemiology, Charité Universitätsmedizin Berlin, Berlin, Germany
  4. 4North-Eastern German Society of Gynecological Oncology, Berlin, Germany
  5. 5Gynäkologisches Tumorzentrum, Sozialstiftung Bamberg – Klinikum am Bruderwald, Bamberg, Germany
  6. 6Frauenklinik, Rotkreuzklinikum München, München, Germany
  7. 7Klinik für Gynäkologie und Geburtshilfe, Städtisches Klinikum Solingen, Solingen, Germany
  8. 8Praxisnetzwerk Hämatologie und intern. Onkologie, St. Josef-Hospital, Troisdorf, Germany
  9. 9Gynäkologisch – onkologische Schwerpunktpraxis, Dr. Busch MVZ, Mühlhausen, Germany


Introduction/Background Every year, around 127,634 women in Europe are diagnosed with ovarian cancer (OC). The majority of the patients detected are diagnosed in advanced stages due to lack or unspecific symptoms and/or no effective screening methods. Hence prognosis is poor. Although most of the patients will be in complete remission following primary cytoreduction and platinum-based chemotherapy, half of the advanced ovarian cancer patients will experience relapse within two years after the diagnosis. In the recurrent therapy option, PARP became a new target in ovarian cancer. Maintenance with PARP inhibitors significantly improved progression free survival in both primary and relapsed high grade ovarian cancer.

We have previously investigated patients’ preferences and expectations from cancer maintenance treatment regimens (Expression IV project). The results from this project indicated that patients choose maintenance therapy primarily to improve the therapeutic outcome and secondarily to improve their quality of life. Based on these results, we considered to perform a fully prospective study characterizing the real-world adherence and progression-free-survival time (PFS), as there is currently limited information available about the adherence to novel therapies such as rucaparib.

Methodology This study will recruit 150 patients with histologically diagnosed platinum-sensitive relapsed high grade ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, that are eligible for rucaparib maintenance therapy according to Summary of Product Characteristics (SmPC). Throughout the study, individual patient data will be collected at baseline and every three months until disease progression or patient’s death whichever occurs first. To capture adherence to rucaparib therapy an adaption (according to the rucaparib therapy) of the ‘Essener Compliance Score’ (ECS) is used. As of June 2022, 13 patients have been included in this study.

Results /

Conclusion /

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.